Should Docetaxel Be Standard of Care for Patients With Metastatic Hormone-Sensitive Prostate Cancer? Pro and Contra

K. Fizazi; C. Jenkins; I. F. Tannock


Ann Oncol. 2015;26(8):1660-1667. 

In This Article


There is a need to improve treatment outcomes for men with metastatic hormone-naive prostate cancer, and although the data from the CHAARTED study in men with high-volume disease suggest substantial improvement in survival, careful consideration of these and other results are required before medical practice is changed. The pro and contra arguments provided above provide an opportunity to share with patients the decision-making process that is required to optimize treatment of a man presenting with metastatic prostate cancer.